Association between Cytokine Production and Disease Severity in Alzheimer’s Disease
-
Farahzad Jabbari Azad
,
Ali Talaei
,
Houshang Rafatpanah
,
Hadis Yousefzadeh
,
Rahele Jafari
,
Andishe Talaei
,
Reza Farid Hosseini
,
Majid Jafari
Abstract
The role of transforming growth factor (TGF)-β1, interferon (IFN)-γ, interleukin (IL)-2, IL-3, and IL-6 in the pathogenesis of Alzheimer's Disease (AD) has long been reported in literature. In this case-control study, the concentrations of these cytokines in altered T lymphocytes, as well as serum vitamin B12, have been compared in terms of factors such as, age, the clinical course and the patients' disease risk. 40 patients who met the DSM-IV-TR criteria of AD were selected and an age- and gender-matched control group was recruited. The participants' cognitive performance was measured according to the Mini Mental State Examination (MMSE), the Global Deterioration Scale (GDS) and Clinical Dementia Ratio (CDR). The levels of cytokines were measured in supernatants of lymphocytes culture, using assays of ELISA and atomic absorption. Higher levels of IL-6 and IFN-γ were found more in the altered T lymphocytes of the AD patients rather than in the control individuals. Furthermore, a marginal significant difference was found between the TGF-β levels of the two study groups. Regression analysis of CDR score and cytokines showed the inverse significant correlation between CDR score and IFN-γ levels. Furthermore, the relation between MMSE scores and IFN-γ was significant, meaning that by increasing MMSE score, IFN-γ level was significantly increased. This study suggests that the levels of IL-6 and IFN-γ are significantly increased in altered T lymphocytes of AD patients, as compared to those who are not inflicted with AD, and that they are related to the patient's age. Also, IFN-γ is related to the severity stage of the AD.
1. Shabestari M, Jabbari F, Hosseni RF, Rezaee SR, Gharivani Y, Valizadeh N, et al. Human T Lymphotropic Virus Type I (HTLV-I) is a Risk Factor for Coronary Artery Disease. Iran J Basic Med Sci; Vol 2013;16(3):224-7.
2. Hosseini RF, Azad FJ, Talaee A, Miri S, Mokhber N, Hosseini FF, et al. Assessment of the immune system activity in Iranian patients with Major Depression Disorder (MDD). Iran J Immunol 2007; 4(1):38-43.
3. Zilka N, Ferencik M, Hulin I. Neuroinflammation in Alzheimer's disease: protector or promoter? Bratisl Lek Listy 2006; 107(9-10):374-83.
4. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer’s disease. Neurobiol Aging 2000; 21(3):383-421.
5. Tuppo EE, Arias HR. The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol 2005;37(2):289-305.
6. Griffin W, Stanley L, Ling C, White L, MacLeod V, Perrot L, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A 1989;86(19):7611-5.
7. Jones S, Small B, Fratiglioni L, Backman L. Predictors of cognitive change from preclinical to clinical Alzheimer's disease. Brain Cogn 2002; 49(2):210-3.
8. Hull M, Strauss S, Berger M, Volk B, Bauer J.Inflammatory mechanisms in Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 1996; 246(3):124-8.
9. Flanders KC, Ren RF, Lippa CF. Transforming growth factor-betas in neurodegenerative disease. Prog Neurobiol 1998; 54(1):71-85.
10. Breitner JC. Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: a current appraisal. Neurobiol Aging 1996; 17(5):789-94.
11. Tarkowski E. Cytokines in dementias. Curr Drug Targets Inflamm Allergy 2002; 1(2):193-200.
12. Bauer J, Strauss S, Schreiter-Gasser U, Ganter U, Schlegel P, Witt I, et al. Interleukin-6 and alpha-2- macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS lett 1991; 85(1):111-4.
13. van der Wal EA, Gómez-Pinilla F, Cotman CW.Transforming growth factor-[beta] 1 is in plaques in Alzheimer and Down pathologies. Neuroreport 1993;4(1):69-72.
14. Yamada T, Horisberger M, Kawaguchi N, Moroo I, Toyoda T. Immunohistochemistry using antibodies to α- interferon and its induced protein, MxA, in Alzheimer's and Parkinson's disease brain tissues. Neurosci Lett 1994;181(1-2):61-4.
15. Araujo DM, Lapchak PA. Induction of immune system mediators in the hippocampal formation in Alzheimer's and Parkinson's diseases: selective effects on specific interleukins and interleukin receptors. Neuroscience 1994;61 (4):745-54.
16. Bunout D, Barrera G, Hirsch S, Gattas V, de la Maza MP, Haschke F, et al. Effects of a nutritional supplement on the immune response and cytokine production in free- living Chilean elderly. JPEN J Parenter Enteral Nutr 2004; 28(5):348-54.
17. Scalabrino G, Carpo M, Bamonti F, Pizzinelli S, D'Avino C, Bresolin N, et al. High tumor necrosis factor-α in levels in cerebrospinal fluid of cobalamin-deficient patients. Ann Neurol 2004; 56(6):886-90.
18. Yamashiki M, Nishimura A, Kosaka Y. Effects of methylcobalamin (vitamin B12) on in vitro cytokine production of peripheral blood mononuclear cells. J Clin Lab Immunol 1992; 37(4):173-82.
19. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. Washington. DC.: American Psychiatric Association;2000.
20. Vasto S, Candore G, Listì F, Balistreri CR, Colonna- Romano G, Malavolta M, et al. Inflammation, genes and zinc in Alzheimer's disease. Brain Res Rev 2008;58(1):96-105.
21. Britschgi M, Wyss-Coray T. Systemic and acquired immune responses in Alzheimer's disease. Int Rev Neurobiol 2007; 82:205-33.
22. Mrak RE, Griffin WS. Potential inflammatory biomarkers in Alzheimer's disease. J Alzheimers Dis 2005; 8(4):369-75.23. Politis A, Olgiati P, Malitas P, Albani D, Signorini A, Polito L, et al. Vitamin B12 levels in Alzheimer's disease: association with clinical features and cytokine production. J Alzheimers Dis 2010; 19(2):481-8.
24. Li Y, Liu L, Kang J, Sheng JG, Barger SW, Mrak RE, et al. Neuronal–glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression. J Neurosci 2000; 20(1):149-55.
25. Sheng JG, Jones RA, Zhou XQ, McGinness JM, Van Eldik LJ, Mrak RE, et al. Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's disease: potential significance for tau protein phosphorylation. Neurochem Int 2001; 39(5-6):341-8.
26. Sheng J, Zhu S, Jones R, Griffin W, Mrak R. Interleukin-1 Promotes Expression and Phosphorylation of Neurofilament and< i> tau</i> Proteins< i> in Vivo</i>. Exp Neuro 2000; 163(2):388-91.
27. Griffin WST, Sheng JG, Roberts GW, Mrak RE.Interleukin-1 Expression in Different Plaque Types in Alzheimer's Disease: Significance in Plaque Evalution. J Neuropathol Exp Neurol 1995; 54(2):276-81.
28. Mehlhorn G, Hollborn M, Schliebs R. Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology. Int J Dev Neurosci 2000; 18(4-5):423-31.
29. Luterman JD, Haroutunian V, Yemul S, Ho L, Purohit D, Aisen PS, et al. Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. Arch Neurol 2000; 57(8):1153-60.
30. Wood JA, Wood PL, Ryan R, Graff-Radford NR, Pilapil C, Robitaille Y, et al. Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1 beta or IL-
1RA but increases in the associated acute phase proteins IL-6, alpha 2-macroglobulin and C-reactive protein. Brain Res 1993; 629(2):245-52.
31. Araujo DM, Lapchak PA. Induction of immune system mediators in the hippocampal formation in Alzheimer's and Parkinson's diseases: selective effects on specific interleukins and interleukin receptors. Neuroscience 1994; 61(4):745-54.
32. Martı nez M, Fernández-Vivancos E, Frank A, De la Fuente M, Hernanz A. Increased cerebrospinal fluid fas (Apo-1) levels in Alzheimer’s disease: relationship with IL-6 concentrations. Brain Res 2000; 869(1):216-9.
33. Blum-Degena D, Müller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 1995;202(1):17-20.
34. März P, Heese K, Hock C, Golombowski S, Müller- Spahn F, Rose-John S, et al. Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett 1997; 239(1):29-32.
35. Rainero I, Bo M, Ferrero M, Valfre W, Vaula G, Pinessi L. Association between the interleukin-1alpha gene and Alzheimer's disease: a meta-analysis. Neurobiol Aging 2004; 25(10):1293-8.
36. Lee KS, Chung JH, Choi TK, Suh SY, Oh BH, Hong CH.Peripheral cytokines and chemokines in Alzheimer’s disease. Dement Geriatr Cogn Disord 2009; 28(4):281-7.
37. Chao C, Ala T, Hu S, Crossley K, Sherman R, Peterson P, et al. Serum cytokine levels in patients with Alzheimer's disease. Clin Diagn Lab Immunol 1994;1(4):433-6.
38. Butovsky O, Talpalar AE, Ben-Yaakov K, Schwartz M.Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective. Mol Cell Neurosci 2005;29(3):381-93.
39. Chao CC, Molitor TW, Hu S. Neuroprotective role of IL-4 against activated microglia. J Immunol 1993;151(3):1473-81..
| Files | ||
| Issue | Vol 13, No 6 (2014) | |
| Section | Articles | |
| Keywords | ||
| Alzheimer’s Disease (AD) Cytokine Vitamin B12 | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
